ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2034

Magnetic Resonance Imaging Is a Reliable Tool to Monitor Chronic Non-Bacterial Osteomyelitis in Children

Grazia Minardo1, Giulia Zanon1, Simone Corradin2, Pietro Zucchetta3, Giorgia Martini4, Fabio Vittadello1 and Francesco Zulian5, 1Department of Pediatrics, University of Padua, Padua, Italy, 2Institute of Radiology, University of Padua, Padua, Italy, 3Department of Nuclear Medicine, University of Padua, Padua, Italy, 4Department of Pediatrics,, University of Padua, Padua, Italy, 5Department of Pediatrics, University of Padua, Padova, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Chronic recurrent multifocal osteomyelitis (CRMO), Magnetic resonance imaging (MRI), outcome measures and pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Chronic non-bacterial osteomyelitis (CNO) is a rare condition characterized by inflammatory bone lesions with no detectable infectious agents. It may be unifocal (U-CNO) or multifocal (M-CNO) and have a monophasic or relapsing course. Various laboratory or imaging parameters have been proposed as possible outcome measures but none has been validated, yet.  

The present study was aimed to define the role of laboratory parameters and imaging tools (MRI and bone scinti-scan, BS) in detecting disease activity in patients with CNO.

Methods:

Patients with CNO, lasting longer than 6 months, were followed every 3-4 months. Laboratory inflammatory parameters (ESR, CRP, WBC, Hb, PLT, SAA), MRI and BS were performed at diagnosis, at the time of clinical relapse or at least yearly in all patients. Clinically, active disease was considered in presence of bone pain needing analgesics or second line therapy. Bone lesions were considered active on MRI in the presence of bone marrow edema (BME) associated to soft tissue inflammation (STI) including perilesional effusion and edema. As resulted in recent sport medicine studies (1), BME alone was not considered a parameter of activity (3). Disease activity at BS was defined by signal intensity, number and extension of hyperactive sites. A single radiologist and nuclear medicine practitioner, blinded on patients’ clinical status, reviewed all MRI and BS independently. Sensitivity, specificity and positive and negative predictive value (PPV, NPV) for disease activity detection of laboratory markers, MRI and BS were calculated by comparing data with clinical status of the patients at different time points.

Results:

16 CNO patients entered the study. 9 had UF-CNO, 7 had MF-CNO, mean age at disease onset  10,8 years (range 2.33-18.5), 54% were female. Disease duration at diagnosis was longer in patients with UF-CNO (14.2 vs 10.1 months). Localized bone pain was the leading symptom at onset in all patients; systemic symptoms, such as fever and fatigue, were more frequent in MF-CNO. At onset WBC was normal, CRP and ESR were elevated in 69.2%, especially in MF-CNO. After median 3 years follow up, 43.7% of patients had no symptoms and were off-therapy. At disease onset, all patients were evaluated by MRI and BS then, during the follow-up, 11 patients repeated BS once (T1), 13 patients repeated MRI once (T1) and 8 twice (T2). At disease onset, all 16 MRI showed BME with STI. Of the 21 follow up MRIs, 5 (23%) completely normalized, 7 (33%) showed only BME, 9 (42%) showed pathological changes. At disease onset all BS showed active lesions with mean 2.1 hyperactive sites (range 1-5). Of the 12 follow-up BS, 5 showed total remission, 3 partial remission and 4 persistent disease activity.

MRI sensitivity ranged between 0.83 and 1.00, specificity 1.00, PPV was 1.00, NPV ranged between 0.86 and 1.00. BS sensitivity was 0.83, specificity 0.74, PPV 0.76, NPV 0.80. Laboratory parameters correlated poorly with disease clinical status.

Conclusion:

MRI is a reliable tool for monitoring CNO in pediatric patients. BS overestimates disease activity, especially in UF-CNO. Laboratory inflammatory parameters are of limited utility. A validation study in a larger patients’ cohort is needed to confirm these preliminary findings.


Disclosure:

G. Minardo,
None;

G. Zanon,
None;

S. Corradin,
None;

P. Zucchetta,
None;

G. Martini,
None;

F. Vittadello, None; F. Zulian,

Ilaris,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/magnetic-resonance-imaging-is-a-reliable-tool-to-monitor-chronic-non-bacterial-osteomyelitis-in-children/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology